---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-042877"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T17:01:04.129668+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch transfers FIN-524 ulcerative colitis program to Takeda for clinical development

## Summary
- Amendment (Aug 9, 2021) transfers primary development & regulatory responsibility for FIN-524/TAK-524 to Takeda ahead of Phase 1.
- Finch received $10M upfront & $4M in milestones; eligible for up to $176M additional plus mid-to-high single-digit royalties.
- Finch will provide technical support through Phase 1; joint Crohn's disease discovery continues.
- TAK-524 is an orally administered consortia candidate targeting ulcerative colitis via immune modulation.

## SEC filing metadata
- accession: 0001564590-21-042877
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/0001564590-21-042877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/fnch-8k_20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-042877
- JSON: https://secwatch.observer/filing/0001564590-21-042877.json
- Plain text: https://secwatch.observer/filing/0001564590-21-042877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.